Risk factors
Shattuck Labs (STTK) risk factors
Item 1A of every Shattuck Labs, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors49 risks3 new5 dropped11 reworded
Shattuck advanced lead candidate SL-325 into Phase 1 trials while expanding net operating loss carryforwards to $251 million.
Filed Mar 05, 2026 - FY2024 10-K risk factors51 risks
Shattuck Labs is a preclinical biotechnology company with a net loss of $75.4 million in 2024 and an accumulated deficit of $381.7 million. The business is heavily dependent on the clinical success and patent protection of its lead product candidate, SL-325, for inflammatory bowel disease. Operations face substantial dilution risks from equity raises, heavy reliance on third-party manufacturers, and complex intellectual property challenges.
Filed Mar 27, 2025